TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an announcement.
TOT BIOPHARM International Co. Ltd. has announced the approval and implementation of new Terms of Reference for its Nomination Committee, effective July 1, 2025. The committee is tasked with reviewing the board’s structure, identifying qualified director candidates, and ensuring board diversity and independence. This move is expected to enhance the company’s governance and align its board composition with its strategic goals, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a company incorporated in Hong Kong, operating within the biopharmaceutical industry. The company focuses on the development, manufacturing, and commercialization of oncology drugs, aiming to address the needs of cancer patients with innovative therapeutic solutions.
Average Trading Volume: 138,178
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.51B
Learn more about 1875 stock on TipRanks’ Stock Analysis page.